Diagnostics & imaging AI · Chest X-ray AI platform
DeepTek
DeepTek builds FDA-cleared radiology AI, including chest X-ray tools and the Augmento platform for AI-assisted radiology workflows. It is not an MRI acceleration product or ambient documentation scribe.
Strong fit
- Imaging programs that need FDA-cleared chest X-ray AI and a radiology AI workflow platform without buying an enterprise multi-ology triage suite first
- Teams that will measure detection performance and reader time after Augmento or Chest X-Ray AI go live
- Buyers comparing mid-market imaging AI vendors rather than Aidoc-scale platforms
Weak fit
- Sites whose only need is MRI acceleration (Subtle lane)
- Buyers requiring a U.S.-only vendor with no India delivery footprint
- Programs without chest radiograph volume
Bottom line
DeepTek earns a Recommend for mid-market imaging buyers that want FDA-cleared chest X-ray AI plus a radiology AI platform story without paying enterprise triage-platform premiums on day one. Outcomes depend on PACS workflow fit and whether radiologists trust the findings queue. Product depth is chest-forward AI and orchestration - peer to Riverain on thoracic focus, narrower than Aidoc's multi-ology franchise. Implementation is a clinical imaging AI project. Pricing is custom. India-reported revenue near ₹35-38 crore (~$4M class) sits at the low end of our prefer band. Score sits just under Riverain on our diagnostics board.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
DeepTek builds FDA-cleared radiology AI, including chest X-ray tools and the Augmento platform for AI-assisted radiology workflows.
Compare Riverain when ClearRead thoracic CT/XR is the primary shopping list, Aidoc when you need multi-ology triage orchestration, and Subtle when the job is scan acceleration.
Score reflects solid mid-market thoracic AI marks on our diagnostics board.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| DeepTek | 7.1 | 6.8 |
| Riverain Technologies | 7.3 | 6.9 |
| Subtle Medical | 7.2 | 6.8 |
| Aidoc | 7.9 | 7.5 |
| Avicenna.AI | 6.9 | 6.6 |
| Studycast | 7.2 | 6.9 |
| Koios Medical | 6.7 | 6.3 |
| AISAP | 7.0 | 6.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Software licensing for FDA-cleared chest X-ray AI and radiology AI platform modules. |
| What usually drives cost | Sites, study volume, modules, and cloud vs on-prem packaging. |
| What to ask in diligence | Cost at your chest XR volume, FDA indication coverage, and PACS integration scope. |
| Published pricing | Public list price: not published. Expect a clinical imaging AI quote. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get DeepTek to function | |
| Radiology clinical owner plus imaging IT | AI tools fail without both. |
| PACS/RIS/EMR interface path documented | Orphan results queues create safety risk. |
| Agreement on which exam types are in scope | Boiling the ocean delays value. |
| Alert or enhanced-series review staffing plan | Unowned queues become ignored queues. |
| Change control for clinical downtime windows | Surprise viewers during peak lists destroy trust. |
| What will maximize your value | |
| Measure turnaround, reopen rates, or detection metrics named at kickoff | Demo accuracy is not operations. |
| Start with one high-volume exam family | Narrow wins beat empty enterprise banners. |
| Review false positives weekly with radiologists | Noisy tools get turned off. |
| Keep radiologists in native viewers when possible | Extra worklists kill adoption. |
| Document FDA indication coverage vs your protocol mix | Mismatched clearances waste spend. |
| Deal-breakers | |
| No imaging IT or clinical owner. | |
| You refuse any interface work. | |
| You expect ambient scribe outcomes from imaging AI. | |
| Nobody will review alerts or enhanced series. | |
| Legal blocks cloud or vendor PHI paths you require. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope | 2–4 weeks — Exam list, interfaces, success metrics. |
| 2 | Integrate | 4–12 weeks — PACS/RIS/EMR hooks; validation cases. |
| 3 | Pilot | 4–8 weeks — One site or modality family. |
| 4 | Expand | Ongoing — More sites; tuning. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.